India, April 27 -- Shares of Compass Therapeutics Inc. (CMPX) are down more than 63% in pre-market trading despite the company reporting that its investigational antibody Tovecimig achieved a highly statistically significant improvement in progression-free survival in the COMPANION-002 Phase 2/3 study in biliary tract cancer.
The company said the results reinforce Tovecimig's potential to address a major unmet need in patients with limited treatment options.
Biliary tract cancer is an aggressive and rare cancer with poor survival outcomes, especially for patients whose tumors do not carry actionable mutations. In the second-line setting, available therapies typically produce response rates of around 5% and median overall survival of rough...